Literature DB >> 20406921

Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin.

Stefan Hohaus1, Giuseppina Massini, Manuela Giachelia, Barbara Vannata, Valentina Bozzoli, Annarosa Cuccaro, Francesco D'Alo', Luigi Maria Larocca, Reinier A P Raymakers, Dorine W Swinkels, Maria Teresa Voso, Giuseppe Leone.   

Abstract

PURPOSE: Cytokines play a pivotal role in Hodgkin's lymphoma (HL). Because interleukin-6 (IL-6) induces expression of hepcidin, one of the principal regulators of iron metabolism, we studied the contribution of hepcidin in anemia in HL at diagnosis. PATIENTS AND METHODS: Plasma samples from 65 patients with HL were analyzed for hepcidin levels using a combination of weak cation exchange chromatography and time-of-flight mass spectrometry; cytokine levels were analyzed using enzyme-linked immunosorbent assays and parameters of iron metabolism and acute-phase reaction.
RESULTS: Hepcidin plasma levels were significantly higher in HL patients when compared with controls, independent of the presence of anemia (P = .001). In the subset of patients with anemia, hepcidin levels inversely correlated with hemoglobin levels (P = .01). Analyzing parameters of iron metabolism, hepcidin levels showed a positive correlation with ferritin (P < .001) and an inverse correlation to iron and iron-binding capacity. Hepcidin strongly correlated to IL-6 levels (P < .001) but not to IL-10 or thymus and activation-regulated cytokine (TARC)/chemokine (C-C motif) ligand 17 (CCL17) levels. In a multivariate regression analysis, IL-6 and fibrinogen levels were independently associated with hepcidin. Higher hepcidin levels were observed in patients with more aggressive disease characteristics: stage IV disease (P = .01), presence of B symptoms (P = .03), and International Prognostic Score > 2 (P = .005).
CONCLUSION: Our findings suggest that in HL, hepcidin is upregulated by IL-6. Elevated hepcidin levels result in iron restriction and signs of anemia of chronic inflammation, although hepcidin-independent mechanisms contribute to development of anemia in HL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20406921     DOI: 10.1200/JCO.2009.27.6873

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  30 in total

1.  Stromal-derived IL-6 alters the balance of myeloerythroid progenitors during Toxoplasma gondii infection.

Authors:  David B Chou; Brian Sworder; Nicolas Bouladoux; Cindy N Roy; Amiko M Uchida; Michael Grigg; Pamela G Robey; Yasmine Belkaid
Journal:  J Leukoc Biol       Date:  2012-04-09       Impact factor: 4.962

Review 2.  Recognizing unusual manifestations of Hodgkin lymphoma.

Authors:  Nicholas A Barber; Philip J Bierman
Journal:  Curr Hematol Malig Rep       Date:  2012-09       Impact factor: 3.952

Review 3.  Hepcidin and iron homeostasis.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Biochim Biophys Acta       Date:  2012-01-26

Review 4.  The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of hereditary hemochromatosis.

Authors:  Hiroshi Kawabata
Journal:  Int J Hematol       Date:  2017-11-13       Impact factor: 2.490

Review 5.  Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.

Authors:  Rajendra Gharbaran
Journal:  Tumour Biol       Date:  2016-06-18

Review 6.  Hepcidin and iron regulation, 10 years later.

Authors:  Tomas Ganz
Journal:  Blood       Date:  2011-02-23       Impact factor: 22.113

7.  On the prediction of Hodgkin lymphoma treatment response.

Authors:  E J deAndrés-Galiana; J L Fernández-Martínez; O Luaces; J J Del Coz; R Fernández; J Solano; E A Nogués; Y Zanabilli; J M Alonso; A R Payer; J M Vicente; J Medina; F Taboada; M Vargas; C Alarcón; M Morán; A González-Ordóñez; M A Palicio; S Ortiz; C Chamorro; S Gonzalez; A P González-Rodríguez
Journal:  Clin Transl Oncol       Date:  2015-04-21       Impact factor: 3.405

8.  The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study.

Authors:  Antonio Macciò; Clelia Madeddu; Giulia Gramignano; Carlo Mulas; Luciana Tanca; Maria Cristina Cherchi; Carlo Floris; Itaru Omoto; Antonio Barracca; Tomas Ganz
Journal:  Haematologica       Date:  2014-09-19       Impact factor: 9.941

9.  Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children's Oncology Group AHOD 0031 Trial.

Authors:  Anne-Marie Charpentier; Debra L Friedman; Suzanne Wolden; Cindy Schwartz; Bethany Gill; Jenna Sykes; Alisha Albert-Green; Kara M Kelly; Louis S Constine; David C Hodgson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-12-01       Impact factor: 7.038

Review 10.  Iron and cancer: more ore to be mined.

Authors:  Suzy V Torti; Frank M Torti
Journal:  Nat Rev Cancer       Date:  2013-04-18       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.